Hospira Bulks Up Pfizer’s Established Products Unit, But Won’t Speed A Split
Executive Summary
Pfizer’s acquisition of sterile injectables specialist Hospira will strengthen its Global Established Pharmaceutical business, but management said it will need time to determine whether or not to break up the business.
You may also be interested in...
Pfizer's Essential Health Leadership On Why US Biosimilars Will Take Off – Eventually
Essential Health Group President Angela Hwang, Biosimilars President Richard Blackburn and US Biosimilars General Manager John Kennedy discuss the early challenges Pfizer has faced with Inflectra and optimism for the US biosimilars market over the long term.
Pfizer's Essential Health Leadership On Why US Biosimilars Will Take Off – Eventually
Essential Health Group President Angela Hwang, Biosimilars President Richard Blackburn and US Biosimilars General Manager John Kennedy discuss the early challenges Pfizer has faced with Inflectra and optimism for the US biosimilars market over the long term.
Teva Catches A Break On Copaxone 40mg, But For How Long?
An FDA warning letter cites deficiencies at the Pfizer-owned manufacturing facility poised to produce a Momenta/Sandoz generic competitor. It’s unclear how long Pfizer might take to resolve the violations, which include particulates in finished products.